Skip to content

Three Quick Facts: DFS Furniture, AstraZeneca and PetroNeft Resources

Three Quick Facts: DFS Furniture, AstraZeneca and PetroNeft Resources

Three things you need to know in the financial markets this morning from investment writer, Tony Cross.

DFS Furniture

There’s an upbeat trading statement out from DFS Furniture LON:DFS this morning, noting that sales over the last six weeks are running significantly ahead of expectations. The company suggests there are three drivers here – consumers spending disproportionately more on their homes, latent demand as a result of the lockdown and also the strength of the company’s digital offering, It’s not all plain sailing from here however, with the risk of further COVID uncertainty and the prospect of Brexit impacts both having the potential to take a toll on the business in the coming months. For now however perhaps something to cheer.

AstraZeneca

AstraZeneca LON:AZN has issued a note regarding a COVID-19 prevention and treatment therapy. The first participants have been ‘dosed’ in a phase I trial so clearly this is relatively early stage work, but if the medicine is tolerated by patients (there are only 48 of them) then the move to bigger trials will be able to proceed.


PetroNeft Resources

AIM listed PetroNeft Resources [LON:PTR], the Siberian oil producer, has updated the market this morning. The company notes that its production is currently up by around 17% from July 2019 levels, whilst an improvement in market conditions is also being lauded. Management is attributing the improved output to the field optimisation programs which started last year and indicates that other low-cost options to realise further gains here may be used in due course.

Sign up for three quick facts and more with our Free Daily Digest newsletter, every weekday morning.

Share this article

Invest with these platforms

Hargreaves Lansdown

IG

Interactive Brokers

Interactive Investor

Charles Stanley

IG

Interactive Brokers

Charles Stanley

Looking for great investing ideas? Get our free newsletter.

This article does not constitute investment advice.  Do your own research or consult a professional advisor.

Learn with our free 'How to' Guides

Our latest in-depth company reports

On the podcast

Sign up for great investing stock tips

Thanks to our Site Partners

Our partners are established, regulated businesses and we are grateful for their support.

Aquis
CME Group
FP Markets
Pepperstone
Schroders

aberdeen
WisdomTree
ARK
Plus500
CMC Markets
Back To Top